Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 5/20 | 0.72 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SI | P14410 | 1/20 | 0.41 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | DGKA | P23743 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7100995 | 0.88 | FAAH (0.86) | FAAHCNR1CNR2ALDH1A1TRPA1 | |
| SCHEMBL8717357 | 0.86 | FAAH (0.53) | FAAHALDH1A1MGAMGAASI | |
| SCHEMBL7103980 | 0.86 | FAAH (0.96) | FAAHCNR1CNR2NAAADGKA | |
| SCHEMBL11763013 | 0.84 | FAAH (1.00) | FAAHCNR1CNR2NAAADGKA | |
| SCHEMBL4640187 | 0.84 | FAAH (1.00) | FAAHCNR1CNR2NAAADGKA | |
| SCHEMBL97404 | 0.82 | ALDH1A1 (0.65) | FAAHCNR1CNR2ALDH1A1TRPA1 | |
| SCHEMBL6669031 | 0.82 | FAAH (0.50) | FAAHALDH1A1MGAMGAASI | |
| SCHEMBL140522 | 0.81 | — | — | |
| SCHEMBL240282 | 0.81 | MGAM (0.60) | FAAHALDH1A1MGAMGAASI | |
| SCHEMBL6831476 | 0.80 | FAAH (0.48) | FAAHALDH1A1MGAMGAASI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110577940-B | Kluyveromyces marxianus aldehyde ketone reductase KmAKR mutant and application thereof | 浙江工业大学 | 2021-06-08 | — | — | CN | claimed |
| WO-2021057014-A1 | KLUYVEROMYCES MARXIANUS ALDO-KETO REDUCTASE KMAKR MUTANT AND APPLICATION THEREOF | 浙江工业大学 | 2021-04-01 | — | — | WO | claimed |
| CN-110577940-A | Kluyveromyces marxianus aldehyde ketone reductase KmAKR mutant and application thereof | 浙江工业大学 | 2019-12-17 | — | — | CN | claimed |
| CN-110577940-B | Kluyveromyces marxianus aldehyde ketone reductase KmAKR mutant and application thereof | 浙江工业大学 | 2021-06-08 | — | — | CN | disclosed |
| WO-2021057014-A1 | KLUYVEROMYCES MARXIANUS ALDO-KETO REDUCTASE KMAKR MUTANT AND APPLICATION THEREOF | 浙江工业大学 | 2021-04-01 | — | — | WO | disclosed |
| CN-110577940-A | Kluyveromyces marxianus aldehyde ketone reductase KmAKR mutant and application thereof | 浙江工业大学 | 2019-12-17 | — | — | CN | disclosed |
| EP-1378566-B1 | Modified reductase from Penicillium citrinum and its encoding gene | SUMITOMO CHEMICAL CO (JP) | 2008-08-06 | — | — | EP | disclosed |
| EP-1213354-B1 | Process for producing optically active 4-halo-3-hydroxybutanoate | SUMITOMO CHEMICAL CO (JP) | 2007-05-30 | — | — | EP | disclosed |
| EP-1386961-B1 | Modified reductase and its gene and use thereof | SUMITOMO CHEMICAL CO (JP) | 2007-03-21 | — | — | EP | disclosed |
| US-7163814-B2 | Modified reductase and its gene, and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-01-16 | — | — | US | disclosed |
| US-7135318-B2 | Modified reductase and its gene | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-11-14 | — | — | US | disclosed |
| US-20040091902-A1 | Modified reductase and its gene | SUMITOMO CHEMICAL COMPANY, LIMITED | 2004-05-13 | — | — | US | disclosed |
| EP-1386961-A2 | Modified reductase and its gene and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-02-04 | — | — | EP | disclosed |
| EP-1378566-A2 | Modified reductase from Penicillium citrinum and its encoding gene | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-01-07 | — | — | EP | disclosed |
| US-20030134402-A1 | Process for producing optically active 4-halo-3-hydroxybutanoate | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-07-17 | — | — | US | disclosed |
| EP-0999202-B1 | Process for producing 2-alkylidene-4-bromoacetoacetic acid ester | SUMITOMO CHEMICAL CO (JP) | 2003-03-19 | — | — | EP | disclosed |
| US-6469200-B1 | A PROCESS WHICH CAN PROVIDE THE DESIRED 2-ALKYLIDENE-4-BROMOACETOACETIC ACID ESTER BY USING, AS A STARTING MATERIAL, A 4-BROMOACETOACETIC ACID ESTER WHICH CAN BE READILY DERIVED FROM AN ACETOACETIC ACID ESTER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-10-22 | — | — | US | disclosed |
| EP-1213354-A2 | Process for producing optically active 4-halo-3-hydroxybutanoate | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-06-12 | — | — | EP | disclosed |
| EP-0999202-A1 | Process for producing 2-alkylidene-4-bromoacetoacetic acid ester | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-05-10 | — | — | EP | disclosed |
| US-4039570-A | DISPERSING AGENTS | LONZA LTD. (CH) | 1977-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134402-A1 | Process for producing optically active 4-halo-3-hydroxybutanoate | RNGTT, HMBS, POLB | FAAH 3017/4885CNR1 4414/4885CNR2 4324/4885 |
| US-20040091902-A1 | Modified reductase and its gene | BLVRB, DHFR, RRM2 | FAAH 3207/4885CNR1 3836/4885CNR2 4526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.